Characteristics and regulation of 123I-MIBG transport in cultured pulmonary endothelial cells

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 437-442

  Lee, Kyung Han ^a,b   Ko, Bong Ho ^a   Paik, Jin Young ^a   Jung, Kyung Ho ^a   Bae, Jun Sang ^a   Choi, Joon Young ^a   Yearn, Seong Choe ^a   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

123I MIBG; Endothelial cells; Hypoxia; Norepinephrine transporters; Pulmonary disease

Indexed keywords

DESIPRAMINE; IMIPRAMINE; METAIODOBENZYLGUANIDINE I 123; N(G) NITROARGININE METHYL ESTER; NORADRENALIN TRANSPORTER; PHENOXYBENZAMINE; PHORBOL 13 ACETATE 12 MYRISTATE; TRACER; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ARTICLE; CALF (BOVINE); CELL CULTURE; CELL STIMULATION; CELL TRANSPORT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG INHIBITION; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; LUNG DISEASE; LUNG ENDOTHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; CATTLE; CYTOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; PULMONARY ARTERY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; LUNG DISEASES; METABOLIC CLEARANCE RATE; PULMONARY ARTERY; RADIOPHARMACEUTICALS;

EID: 33645973302     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med. 1993;23:231-242.
2. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol. 2002;9:75-94.
3. 123I-metaiodobenzylguanidine. J Nucl Med. 2003;44:1747-1754.
4. 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging. 2005;32:221-228.
5. 123I-MIBG retention. Nucl Med Commun. 2001;22:1083-1088.
6. Suga K, Kume N, Shimizu K, et al. Potential of iodine-123 metaiodobenzylguanidine single-photon emission tomography to detect abnormal functional status of the pulmonary neuroadrenergic system in irradiated lung. Eur J Nucl Med. 1999;26:647-654.
7. Koizumi T, Kubo K, Hanaoka M, et al. Serial scintigraphic assessment of iodine-123 metaiodobenzylguanidine lung uptake in a patient with high-altitude pulmonary edema. Chest. 1999;116:1129-1131.
8. 123I-MIBG pulmonary removal: a biochemical marker of minimal lung endothelial lesions. Eur J Nucl Med. 1990;16:633-637.
9. Bakhle YS, Vane JR. Pharmacokinetic function of the pulmonary endothelium. Physiol Rev. 1974;54:1007-1045.
10. Gillis CN. Measurement of endothelial metabolic functions in vivo. Ann Biomed Eng. 1987;15:183-188.
11. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhoffer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963-985.
12. Iwasawa Y, Gillis CN, Aghajanian G. Hypothermic inhibition of 5-hydroxytryptamine and norepinephrine uptake by the lung: cellular location of amines after uptake. J Pharmacol Exp Ther. 1973;186:498-507.
13. Hughes J, Gillis CN, Bloom FE. The uptake and disposition of dl-norepinephrine in perfused rat lung. J Pharmacol Exp Ther. 1969;169:237-248.
14. Gillis CN, Pitt BR. The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol. 1982;44:269-281.
15. 125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res. 1985;45:6366-6370.
16. Iavarone A, Lasorella A, Servidei T, Riccardi R, Troncone L, Mastrangelo R. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells. J Nucl Biol Med. 1991;35:186-190.
17. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its distribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545-559.
18. Tobes MC, Jacques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26:897-907.
19. Anton M, Wagner B, Haubner R, et al. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004;6:119-126.
20. Altmann A, Kissel M, Zitzmann S, et al. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med. 2003;44:973-980.
21. 125I]meta-iodobenzylguanidine in neuroblastoma cells: evidence of a carrier-mediated efflux. Eur J Cancer. 1995;31A:591-595.
22. Eisenfeld AJ, Axelrod J, Krakoff L. Inhibition of the extraneuronal accumulation and metabolism of norepinephrine by adrenergic blocking agents. J Pharmacol Exp Ther. 1967;156:107-113.
23. Eisenfeld AJ, Krakoff L, Iversen LL, Axelrod J. Inhibition of the extraneuronal metabolism of noradrenaline in the isolated heart by adrenergic blocking agents. Nature. 1967;213:297-298.
24. Gillespie JS, Hamilton DN, Hosie JA. The extraneuronal uptake and localization of noradrenaline in the cat spleen and the effect on this of some drugs, of cold and of denervation. J Physiol. 1970;206:563-590.
25. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine, and serotonin transporters. J Nucl Med. 1993;34:1140-1146.
26. Lode HN, Bruchelt G, Seitz G, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer. 1995;31A:586-590.
27. Montaldo PG, Raffaghello L, Guarnaccia F, Pistola V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer. 1996;67:95-100.
28. 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994;70:97-101.
29. Tseng YT, Padbury JF. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm. 1998;105:1187-1195.
30. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci. 2003;23:4470-4478.
31. Wakayama K, Ohtsuki S, Takanaga H, Hosoya K, Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neurosci Res. 2002;44:173-180.
32. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26:74-84.
33. Gewitz MH, Tait MS. Effects of hypoxia on norepinephrine uptake by developing rabbit lung. Pediatr Pharmacol (New York). 1984;4:109-113.
34. Scherrer-Crosbie M, Mardon K, Cayla J, Syrota A, Merlet P. Alterations of myocardial sympathetic innervation in response to hypoxia. J Nucl Med. 1997;38:954-957.
35. Richalet JP, Merlet P, Bourguignon M, et al. MIBG scintigraphic assessment of cardiac adrenergic activity in response to altitude hypoxia. J Nucl Med. 1990;31:34-37.
36. Tinsley JH, Teasdale NR, Yuan SY. Involvement of PKCdelta and PKD in pulmonary microvascular endothelial cell hyperpermeability. Am J Physiol Cell Physiol. 2004;286:C105-C111.
37. Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther. 1998;287:744-751.